Company research
Launch One Acquisition Corp.
CIK 2015502Updated Sep 24, 2026
LPAA price & chart
Loading TradingView…
NASDAQ:LPAA on TradingView ↗About the company
Launch One Acquisition Corp. is a company set up to merge with and take public an exciting business in healthcare or technology. Listed on Nasdaq under the ticker LPAA, Launch One is led by experienced leaders who want to support game-changing solutions. For more information, contact Jurgen van de Vyver at jurgen@launchpad.vc.
In the news
Recent filings
SCHEDULE 13G/A filing
10-Q filing
Entry into a Material Definitive Agreement · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 1.01, 5.03, 5.07, 9.01
Unregistered Sales of Equity Securities · Other Events
Items 3.02, 8.01
DEFA14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 245,630,529Source | 236,639,418Source |
| Current assets: | ||
| Assets, CurrentUSD | 181,176Source | 1,056,301Source |
| Prepaid Expense and Other Assets, CurrentUSD | 68,844Source | — |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 11,741,137Source | 11,059,180Source |
| Stockholders’ equity: | ||
| Retained Earnings (Accumulated Deficit)USD | -11,560,536Source | -9,949,858Source |
| Stockholders' Equity Attributable to ParentUSD | -11,559,961Source | -9,949,283Source |
| Liabilities and EquityUSD | 245,630,529Source | 236,639,418Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 791,137Source | 109,180Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 791,137Source | 109,180Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -820,192Source | -472,305Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | -230,000,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | 231,322,643Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 30,146Source | 850,338Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 1,611,081Source | 400,002Source |
| Investment Income, InterestUSD | 9,919,832Source | 5,404,164Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | 125,357Source |
| Net Income (Loss) Attributable to ParentUSD | 8,309,154Source | 5,129,519Source |
| Nonoperating Income (Expense)USD | 9,920,235Source | 5,529,521Source |
| Payments to Acquire InvestmentsUSD | — | 230,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating Income (Loss)USD | -1,611,081Source | -400,002Source |
| Net Income (Loss) Attributable to ParentUSD | 8,309,154Source | 5,129,519Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 1,611,081Source | 400,002Source |
| Investment Income, InterestUSD | 9,919,832Source | 5,404,164Source |
| Nonoperating Income (Expense)USD | 9,920,235Source | 5,529,521Source |
Filing attachments
ea024687201ex99-1_launch.htm · 8-K · 2025-06-25
EX-99.1 2 ea024687201ex99-1_launch.htm PRESS RELEASE, DATED JUNE 25, 2025 Exhibit 99.1 Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets Minovia’s mitochondrial augmentation technology (MAT) targets multi-organ clinical benefits; lead program MNV-201 has both FDA Fast Track Designation and Rare Pediatric Disease designation and is prepari…
Read attachment ↗ea024687201ex99-2_launch.htm · 8-K · 2025-06-25
EX-99.2 3 ea024687201ex99-2_launch.htm PRESENTATION, DATED JUNE 25, 2025 Exhibit 99.2 1 Investor Presentation June 2025 CONFIDENTIAL AND PROPRIETARY Disclaimers Disclaimers and Other Important Information This presentation (this “Presentation”) is being furnished solely to (i) recipients that are “qualified institutional buyers” as defined in Rule 144 A of the U. S. Securities Act of 1933, as amended (the “Securities Act”), or institutional “accredited investors” (as defined in Rule 506 of…
Read attachment ↗